Cefamandole, a new parenteral cephalosporin antibiotic, was administered to 23 newbom infants with pustular skin infection due to Staphylococcus aureus for an average duration of 7.5 days. All the patients improved clinically. Elevation of serum glutamic oxaloacetic transaminase and eosinophilia were observed in nine infants each transiently during treatment. There were no abnormalities of renal functions and Coombs' test results remained negative. The levels of cefamandole in serum after either intravenous or intramuscular administration were higher and the mean life was longer than those previously reported in older infants, children, and adults.
Cefamandole (CM), a new semisynthetic cephalosporin antibiotic is more active against Enterobacteriaceae and Enterobacter than currently available cephalosporin preparations (5, 10, 12, 13) . The spectrum also includes ampicillin-resistant strains of Haemophilus influenzae and Staphylococcus aureus resistant to methicillin (11, 12, 14) . Previous studies have demonstrated its efficacy and pharmacokinetics in older infants, children, and adults (1, 4, 9, 14) . Because of its spectrum and ability to achieve therapeutic concentrations in cerebrospinal fluid (9, 16 10.7 mg/dl, respectively, and for mean serum creatinine were 0.7, 0.6, and 0.7 mg/dl, respectively.
DISCUSSION
The serum levels observed in this study were in general considerably higher than the minimal inhibitory concentrations (MICs) against bacteria commonly associated with neonatal infection. We did not determine the MICs of CM against the organisms isolated in our study. Previous studies, however, have shown that the MIC of CM for 100% of the strains of S. aureus ranges from 0.5 to 8 ,ug/ml (10), and for over two-thirds of strains of E. coli and Klebsiella it ranges from 0.5 to 1.0 ,ug/ml. The MICs of CM against Proteus, Salmonella, Shigella, and group B streptococcus are in similar ranges (10) . Against Listeria, however, the MICs of CM are higher (4 to 8 ,tg/ml), and against Enterococcus they are still higher (16 to 32 ,ig/l'l) ('0 2 weeks and its ability to cross the blood-brain barrier in newborn infants. In the absence of information in this area, CM or any other cephalosporin antibiotic cannot be recommended for neonatants in whom systemic infection is suspected.
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